Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a

Marco Battaglini1 | Hugo Vrenken2 | Riccardo Tappa Brocci1 | Giordano Gentile1
Ludovico Luchetti1 | Adriaan Versteeg2 | Mark S. Freedman3 | Bernard M. J. Uitdehaag4
Ludwig Kappos5 | Giancarlo Comi6 | Andrea Seitzinger7 | Dominic Jack8
Maria Pia Sormani9 | Frederik Barkhof2,10 | Nicola De Stefano1

1Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
2Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, The Netherlands
3Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada
4Department of Neurology, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands
5Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and Neurology, Departments of Head, Spine and Neuromedicine, Biomedical Engineering and Clinical Research, University Hospital, University of Basel, Basel, Switzerland
6Casa di Cura Privata del Policlinico, Università Vita-Salute San Raffaele, Milan, Italy
7Global Biostatistics, Merck Healthcare KGaA, Darmstadt, Germany
8Global Medical Affairs, Merck Serono Ltd (an affiliate of Merck KGaA), Feltham, UK
9Department of Health Sciences, University of Genoa, Genoa, Italy
10UCL Institutes of Neurology and Healthcare Engineering, London, UK

Abstract

Background and purpose: In the REFLEX trial (ClinicalTrials.gov identifier: NCT00404352), patients with a first clinical demyelinating event (FCDE) displayed significantly delayed onset of multiple sclerosis (MS; McDonald criteria) when treated with subcutaneous interferon beta-1a (sc IFN β-1a) versus placebo. This post hoc analysis evaluated the effect of sc IFN β-1a on spatio-temporal evolution of disease activity, assessed by changes in T2 lesion distribution, in specific brain regions of such patients and its relationship with conversion to MS.

Methods: Post hoc analysis of baseline and 24-month magnetic resonance imaging data from FCDE patients who received sc IFN β-1a 44 µg once or three times weekly, or placebo in the REFLEX trial. Patients were grouped according to McDonald MS status...
CONVERSION TO MS IN THE REFLEX TRIAL

INTRODUCTION

In the REFLEX trial (ClinicalTrials.gov identifier: NCT00404352), patients with a first clinical demyelinating event (FCDE) displayed significantly delayed onset of McDonald multiple sclerosis (MS) when treated with subcutaneous interferon beta-1a (sc IFN β-1a) versus placebo [1]. This was accompanied by lower occurrence and volume of new T2, T1 hypo-intense, and T1 gadolinium-enhancing (Gd+) lesions [2].

New advances in magnetic resonance imaging (MRI) analysis techniques facilitate further analysis of topographical lesion distribution and frequency. Proton density (PD) magnetic resonance subtraction imaging (SubI) is a relatively new, effective, imaging technique that allows monitoring of patient lesion evolution between time-points [3]. Lesion probability mapping (LPM) enables between-group comparisons of local lesion frequency throughout the brain using voxel-wise statistical analysis [4].

Multiple studies indicate that an increased white matter (WM) lesion load positively correlates with conversion to clinically definite MS (CDMS) [5-8]. Lesion location in specific brain regions has emerged as an important predictor of conversion to CDMS in patients with FCDE [9], as well as being a major factor determining the degree of disability and disease prognosis [9,10]. However, the relationship between the spatio-temporal dynamics of MS lesions and conversion to CDMS needs further elucidation.

This post hoc study of data from the REFLEX trial [1,2] aimed to assess, using LPM of SubI, whether inflammatory activity during the disease course is widespread across the brain or confined to specific areas. In doing so, this may allow for identification of specific brain areas that, if affected by an inflammatory activity, may predict the conversion to MS, and whether sc IFN β-1a affects the development of new/enlarging lesions or promotes the shrinking/disappearing of pre-existing lesions.

METHODS

This study used data from the phase III, placebo-controlled REFLEX clinical trial, which evaluated treatment with sc IFN β-1a 44 μg once (qw) or three times weekly (tiw) in patients with a FCDE. Details of this trial are described in detail elsewhere [1,2].

Patients

A total of 457 patients with a FCDE provided data for analysis. Patients were grouped according to their conversion to McDonald MS status (converted to McDonald MS vs. non-converted patients), which was defined by the 2005 McDonald criteria [11]. A secondary analysis grouping patients as converters or non-converters to CDMS using the Poser criteria was also performed (see Appendix S1) [12]. Patients were further analyzed according to their treatment regimen (sc IFN β-1a 44 μg qw or tiw vs. placebo). Those treated with sc IFN β-1a versus placebo showed significantly lower new lesion frequency in specific brain regions (cluster corrected): ATR (p = 0.025), superior longitudinal fasciculus (p = 0.042), CST (p = 0.048), and inferior longitudinal fasciculus (p = 0.048).

Conclusions: T2 lesion distribution in specific brain locations predict conversion to McDonald MS and show significantly reduced new lesion occurrence after treatment with sc IFN β-1a in an FCDE population.

KEYWORDS

first clinical demyelinating event, interferon-beta, lesions, white matter tracts
followed by statistical analysis.

The methodology for the creation and analysis of Subls is described in full in Appendix S1. Briefly, prior to generating Subls, slice-to-slice variation in signal intensity on the PD-weighted images was corrected. Baseline and Month 24 PD images were registered to a common halfway space using a similar procedure to that used in the FSL-SIENA software in which the required transformation matrix was determined from the corresponding T2-weighted images obtained from the same dual-echo acquisition. The screening scan images were subtracted from the corresponding Month 24 images to obtain the Subls. To give a robust analysis, the Subls were further normalized to account for the differences between the sites and MRI scanners from which the images were obtained.

Analysis of Subl lesion volume change was restricted to evaluation of manual lesion masks, and lesions were classified as follows. First, individual lesions were classified as new, disappearing, or changing based on comparison of the expert manual lesion outlines of both time-points. Specifically, if a lesion outline was present on the Month 24 image but not the baseline image, the lesion was classified as a new lesion; vice versa, a lesion outline present on the baseline image without a corresponding lesion outline on the Month 24 image was classified as a disappearing lesion. Finally, wholly or partially overlapping lesion outlines on both time-points’ images were classified as changing lesions. Volume change was analyzed for individual lesions (see Appendix S1), and total lesion volume change was calculated from these individual changes. Within changing lesions, the net volume change thus obtained was used to determine whether to classify the lesion as a net growing or shrinking lesion. All voxels belonging to lesion outlines were assigned a label indicating the type of lesion for use in the LPM analyses.

**Image post-processing**

A study template representative of the study population was created as described in Appendix S1. This study-group-specific template was used for all the regional and voxel-wise analyses (baseline and longitudinal). For each patient group comparison (i.e., converters to McDonald MS versus non-converters, and sc IFN β-1a-treated versus placebo), a baseline new/enlarging and shrinking/disappearing lesion mask for each patient was registered to template space, followed by statistical analysis.

**Global analysis**

At baseline, between-group differences in age, sex, and lesion volume were assessed for patients converting to McDonald MS versus non-converters, and patients who were treated with sc IFN β-1a versus placebo. In the longitudinal analysis (baseline to Month 24), the number and volume of lesions were measured for each class of new/enlarging and shrinking/disappearing lesion masks.

**Tract analysis**

For each patient group, the numbers of new/enlarging and shrinking/disappearing lesions were determined for nine WM tracts from the Johns Hopkins University White-Matter Tractography Atlas provided with the FSL Library. The tracts analyzed were: anterior thalamic radiation (ATR), cingulum, cortical spinal tract (CST), forceps major, forceps minor, inferior fronto-occipital fasciculus (IFOF), inferior longitudinal fasciculus (ILF), superior longitudinal fasciculus (SLF), and uncinate fasciculus. For each mask, the number of connected clusters within each WM tract was counted; only clusters greater than three voxels were retained.

**Voxel-wise analysis**

For each patient group, a baseline LPM was generated by merging and averaging all standard space lesion masks, according to the procedure described by Di Perri and colleagues [4]. For the longitudinal analysis, LPMs of new/enlarging and shrinking/disappearing lesions were also generated. On the LPMs, the signal intensity at each voxel represents the probability of a voxel being a lesion.

**Statistical analysis**

For the global baseline analysis, a Mann–Whitney U test determined any statistically significant differences in age and lesions between groups. An Fisher exact test was used for between-group comparisons for sex (significance defined as \( p < 0.05 \)). For the longitudinal global analysis, in terms of changes from baseline to Month 24, a between-group comparison for the number and volume change of each type of lesion was performed using a non-parametric permutation test (adjusted for age, sex, center, and conversion or treatment; significance defined as \( p < 0.05 \)).

The longitudinal tract analysis used a non-parametric permutation test within the General Linear Model framework to assess the differences in number of new/enlarging and shrinking/disappearing lesions, between those converting to McDonald MS and non-converting patients, and between sc IFN β-1a- and placebo-treated patients, for each WM region (adjusted for age, sex, center, and conversion or treatment; significance defined as \( p < 0.01 \)). To test whether differences in treatment effect (sc IFN β-1a vs. placebo) between tracts were likely real or related to statistical power, these age- and sex-adjusted comparisons were also performed using a mixed model adjusted for treatment-by-tract interactions (significance defined as \( p < 0.01 \)).
Voxel-wise between-group differences in lesion frequency at baseline, adjusted for age and sex, and new lesion frequency at Month 24 (longitudinal analysis), adjusted for age, sex, center, and conversion or treatment, were analyzed using an unpaired t-test within the General Linear Model framework using the Randomise tool from the FMRIB software library (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki; significance defined as p < 0.05 and corrected for multiple comparisons). In the voxel-wise baseline and longitudinal analyses, the anatomical location of the local maxima within significant clusters were established using the probabilistic tractography WM atlas included with FSL.

RESULTS

Baseline analysis of lesion distribution and frequency

In total, 457 baseline MRI scans obtained from REFLEX trial participants were available for post hoc analysis; 307 were treated with sc IFN β-1a (i.e., sc IFN β-1a 44 μg qw or tiw) versus 150 who received placebo. Of these, 342 patients converted to McDonald MS and 115 were non-converters. LPMs were created for 442 patients: 333 converting to McDonald MS versus 109 non-converters, and 299 treated with sc IFN β-1a (qw n = 142; tiw: n = 157) versus 143 placebo recipients. Fifteen scans were discarded at baseline due to errors of nonlinear registration on the specific study-group template.

The baseline demographics and MRI characteristics of the patients included in the LPM analyses stratified by conversion to McDonald MS status and treatment group are presented in Table 1.

Patients converting to McDonald MS versus non-converters

Of the 442 patients with MRI scans available at baseline, those who subsequently converted to McDonald MS were significantly younger than those who did not convert (mean age 30.5 vs. 32.6 years; p < 0.03) and had a significantly greater overall mean lesion volume (3.92 vs. 1.90 cm³; p < 0.001). No significant sex-related differences were apparent for those converting to McDonald MS versus non-converting groups (Table 1).

Using the voxel-wise approach, baseline LPMs showed that there was little difference between the maximum local probability of lesions for patients who converted to McDonald MS (15.9%) and those who did not convert (13.8%; Figure 1a,b). However, the overall distribution of lesions across the brain differed between the groups, and the number of cerebral voxels occupied by lesions was 2.8-fold larger in those converting to McDonald MS compared with the non-converting group. In addition, a higher frequency of lesions (p < 0.05, cluster-corrected) was present in the projection, association, and commissural WM tracts of patients who converted to McDonald MS compared with non-converters (Figure 1c). In particular, lesion frequency was higher in the ATR (left and right), CST (left and right), forceps major (right), cingulum (right), and IFOF (left) tracts of patients who converted to McDonald MS (p < 0.001; Table S1).

sc IFN β-1a- versus placebo-treated patients

Among the 442 patients with MRI scans available at baseline, there were no significant differences in mean age (31.1 vs. 30.8 years), proportion of females (63.2% vs. 66.4%) or mean lesion volume (3.58 vs. 3.08 cm³) between the sc IFN β-1a- and placebo-treated groups (Table 1).

Voxel-wise analysis of baseline LPMs showed that the maximum local probability of lesions at baseline was comparable between sc IFN β-1a-treated (15.4%) and placebo-treated (15.3%) patients, and in both groups reached the left side of the CST. The overall lesion distribution across the brain was similar in both groups, with no observed differences in the frequency of lesions in specific WM tracts (Figure 1d,e).

Longitudinal analysis of lesion distribution and frequency

Longitudinal analysis of lesion occurrence utilized 407 SubI scans, including 305 patients converting to McDonald MS versus 102 non-converters, and 273 patients treated with sc IFN β-1a versus 134 placebo recipients. Longitudinal MRI data from 35 patients were not included because 17 subtraction images failed during creation, two had artefacts, two had errors in registration, two were mutually inverted in orientation, and 12 images from Month 24 were unavailable.

The baseline patient demographics and MRI characteristics for this population are summarized in Table S2.

Patients converting to McDonald MS versus non-converters

Patients who converted to McDonald MS had a higher mean (±standard deviation [SD]) total number of (6.48 ± 9.3) and volume increase (0.77 ± 1.3 cm³) due to new/enlarging lesions compared with patients who did not convert (1.15 ± 2.1 and 0.10 ± 0.2 cm³, respectively; both p < 0.001), when adjusted for age, sex, center, and treatment. Patients who converted to McDonald MS also had a higher mean (±SD) number of (5.41 ± 6.9) and a larger mean volume decrease (0.85 ± 1.8 cm³) due to shrinking/disappearing lesions compared with patients who did not convert (1.84 ± 3.2 and 0.39 ± 1.2 cm³, respectively; both p < 0.001), when adjusted for age, sex, center, and treatment.

Compared with patients who converted to McDonald MS, the number of new/enlarging and shrinking/disappearing lesions...
(adjusted for age, sex, center, and treatment) was lower for those who did not convert in all WM tracts analyzed ($p < 0.01$ and $p < 0.05$, respectively; Table 2).

In the voxel-wise analysis, there was no difference between the maximum local probability of new/enlarging lesions for patients who converted to McDonald MS versus patients who did not (2.94%; Figure 2a,b). However, the distribution of new lesions across the brain was very different in those patients who converted to McDonald MS versus patients who did not. The number of cerebral voxels occupied by new/enlarging lesions in the converting to McDonald MS group was 14.6-fold greater than in the non-converting group. Patients who

| TABLE 1 | Patient demographics and magnetic resonance imaging characteristics in the baseline lesion probability map analysis |
|----------|---------------------------------------------------------------------------------------------------------------|
| Parameter | Converters to CDMS (n = 333) | Non-converters to CDMS (n = 109) | Placebo (n = 143) | sc IFN β-1a (n = 299) |
| Baseline demographics | | | | |
| Age, years | Mean ± SD | 30.5 ± 8.1 | 32.6 ± 8.6 | 30.8 ± 8.0 | 31.1 ± 8.4 |
| | Median (Q1, Q3) | 29.0 (24.0, 36.0) | 32.0 (25.0, 38.0) | 30 (24.0, 37.0) | 30.0 (24.0, 37.0) |
| Female, n (%) | 207 (62.2) | 77 (70.6) | 95 (66.4) | 189 (63.2) |
| Classification of FCDE as monofocal $^a$, n (%) | 176 (52.9) | 78 (71.6) | 81 (56.6) | 173 (57.9) |
| Steroid use at FCDE, n (%) | 233 (70.0) | 76 (69.7) | 97 (67.8) | 212 (70.9) |
| EDSS score | Mean ± SD | 1.56 ± 0.74 | 1.36 ± 0.82 | 1.47 ± 0.75 | 1.53 ± 0.77 |
| | Median (Q1, Q3) | 1.50 (1.00, 2.00) | 1.50 (1.00, 2.00) | 1.50 (1.00, 2.00) | 1.50 (1.00, 2.00) |
| MRI characteristics | | | | |
| T1 Gd+ lesions, n | 524 | 45 | 147 | 422 |
| | Mean ± SD | 1.57 ± 3.1 | 0.41 ± 1.0 | 1.03 ± 1.9 | 1.41 ± 3.1 |
| | Median (Q1, Q3) | 0.0 (0.0, 2.0) | 0.0 (0.0, 0.0) | 0.0 (0.0, 1.0) | 0.0 (0.0, 1.0) |
| Presence of at least 1 T1 Gd+ lesion, n (%) | 161 (48.3) | 30 (27.5) | 57 (39.9) | 134 (44.8) |
| T1 hypo-intense lesions, n | 2162 | 364 | 728 | 1798 |
| | Mean ± SD | 6.49 ± 7.7 | 3.34 ± 4.9 | 5.09 ± 7.4 | 6.01 ± 7.2 |
| | Median (Q1, Q3) | 4.0 (1.0, 8.3) | 1.0 (0.0, 4.3) | 3.0 (0.3, 7.8) | 4.0 (1.0, 8.0) |
| T1 hypo-intense lesion volume, mm$^3$ | | | | |
| | Mean ± SD | 772.8 ± 1125.9 | 466.8 ± 1013.1 | 623.7 ± 1008.0 | 732.6 ± 1149.8 |
| | Median (Q1, Q3) | 343.3 (83.0, 989.9) | 80.1 (0.0, 383.2) | 177.4 (4.3, 778.2) | 263.2 (52.2, 935.5) |
| T2 lesions, n | 8502 | 1289 | 2829 | 6962 |
| | Mean ± SD | 25.53 ± 21.3 | 11.83 ± 10.8 | 19.78 ± 19.6 | 23.28 ± 20.3 |
| | Median (Q1, Q3) | 19 (11.0, 33.0) | 8 (4.0, 17.0) | 14 (6.3, 25.8) | 18 (8.0, 32.0) |
| ≥9 T2 lesions, n (%) | 277 (83.2) | 45 (41.3) | 99 (69.2) | 223 (74.6) |
| T2 lesion volume, mm$^3$ | | | | |
| | Mean ± SD | 3915.1 ± 4230.5 | 1899.4 ± 2753.5 | 3077.3 ± 3792.1 | 3581.0 ± 4107.6 |
| | Median (Q1, Q3) | 2429.1 (1035.0, 5035.4) | 755.3 (252.5, 2150.8) | 1436.3 (640.2, 3963.9) | 2131.5 (783.3, 4609.0) |
| Normalized brain volume, cm$^3$ | | | | |
| | Mean ± SD | 1535.9 ± 69.5 | 1540.6 ± 66.2 | 1543.3 ± 64.1 | 1534.1 ± 70.7 |
| | Median (Q1, Q3) | 1544.7 (1490.5, 1582.7) | 1533.4 (1505.9, 1585.7) | 1546.8 (1497.8, 1588.7) | 1536.9 (1493.2, 1580.1) |

Abbreviations: CDMS, clinically definite multiple sclerosis; EDSS, Expanded Disability Status Scale; FCDE, first clinical demyelinating event; Gd+, gadolinium-enhancing; IFN, interferon; LPM, lesion probability map; MRI, magnetic resonance imaging; Q, quartile; sc, subcutaneous; SD, standard deviation.

$^a$According to the adjudication committee.
converted to McDonald MS had a higher new/enlarging lesion frequency than those who did not convert in the projection, association, and commissural WM tracts ($p < 0.05$, cluster-corrected; Figure 2c). New lesion frequency was higher in the ATR (left) and CST (right) tracts of patients who converted to McDonald MS compared with those who did not convert ($p < 0.05$; Table S3). No differences in lesion distribution were observed for shrinking/disappearing lesions in patients who converted to McDonald MS compared with those who did not convert.

Additional voxel-wise analyses were performed comparing patients who converted to CDMS ($n = 110$) with those who did not convert ($n = 296$; see Appendix S1). Although patient distribution between converting and non-converting groups differed using the two definitions of conversion, new brain lesions were more frequently found in converting than non-converting patients in the same regions using both definitions. The affected regions were less extensive when conversion was defined as CDMS compared with McDonald MS.

Patients treated with sc IFN β-1a had a lower mean (±SD) number of new/enlarging lesions ($n = 273; 6.9 ± 10$) compared with placebo-treated patients ($n = 134; 10.9 ± 16$, $p < 0.01$), while the lesion volume increase of new/enlarging lesions showed a trend towards reduction in treated patients ($0.47 ± 0.99$ vs. $0.88 ± 1.48 \text{ cm}^3$, $p = 0.067$), after adjusting for age, sex, center, and conversion. There was no difference in the mean (±SD) number and volume change of shrinking/disappearing lesions for sc IFN β-1a-treated ($9.7 ± 12$ and $-0.71 ± 1.53 \text{ cm}^3$, respectively) and placebo-treated patients ($8.6 ± 11.0$ and $-0.80 ± 1.87 \text{ cm}^3$, respectively).

The number of new/enlarging lesions was significantly reduced in sc IFN β-1a-treated patients compared with placebotreated patients in the ATR, cingulum, CST, ILF, and SLF ($n = 407$; Table 3). When analyses were adjusted for treatment-by-tract interactions, the differences between sc IFN β-1a- and
placebo-treated patients in the number of such lesions were no longer significant (p = 0.9). This suggests that differences were widespread rather than tract-related, not reaching statistical significance in those tracts that, irrespective of treatment, showed a low frequency of new/enlarging lesions. Within the different tracts analyzed, no significant differences between sc IFN β-1a- and placebo-treated patients were observed for the number of shrinking/disappearing lesions.

In voxel-wise analyses, the maximum local probability of new/enlarging lesions was almost 2-fold higher for placebo recipients (5.2%) compared with sc IFN β-1a-treated patients (3.2%). The overall volume of new/enlarging lesions was similar in sc IFN β-1a- and placebo-treated patients (153.3 vs. 146.1 cm³; ratio for placebo- to sc IFN β-1a-treated patients: 0.95; Figure 2d,e). Patients treated with sc IFN β-1a showed lower new lesion frequency than placebo-treated patients in specific brain regions (cluster-corrected) including the ATR (p = 0.025), SLF (p = 0.042), CST (p = 0.048), and ILF (p = 0.048; Figure 3). In specific areas of the CST (left and right), ATR (left), ILF (right), forceps major (left), and SCR (right), new lesion frequency was lower in sc IFN β-1a-treated versus placebo-treated patients (Table S4). In specific areas of the forceps major (right) and SCR (left), new lesion frequency was greater in sc IFN β-1a-treated compared with placebo-treated patients (Table S5).

No significant differences were observed in the voxel-wise analysis for sc IFN β-1a- and placebo-treated patients for shrinking/disappearing lesions.

Additional voxel-wise analyses, performed with adjustment for conversion to CDMS instead of McDonald MS, showed that the same regions of importance were found with respect to those obtained by previous analysis but with smaller (half) spatial extension (see Appendix S1).

**DISCUSSION**

The definition of conversion to McDonald criteria MS is based on radiological disease progression. Thus, it is not surprising in the present study that new/enlarging lesion accumulation over 2 years was globally more prominent in patients who converted to McDonald MS than in those who did not convert. However, we identified specific WM regions where inflammatory activity related to MS was more pronounced, using LPM methodology to map the distribution of new/enlarging lesions from Subls, highlighting the clinically relevant role of specific tracts such as the CST and ATR. Interestingly, the absence of treatment-by-tract interactions strongly suggests that suppression of this activity does not follow specific neural pathways, thus supporting the view that although microstructural changes in MS are widespread across selective brain areas, there is no drug-specific tract activity.

To test whether the clinical transition from FCDE to MS was driven by a higher presence of new/enlarging lesions in selective brain areas, we repeated our analyses both at global and voxel-wise levels using CDMS Poser criteria [12], which is a more clinical definition of conversion and is not related to radiological features. Although using this definition of conversion changed the composition of the analysis groups, results were in general agreement with those using McDonald criteria. Pathological inflammatory (lesional) activity was again more pronounced in patients who converted than in those who did not convert, and, most importantly, the areas involved in driving the conversions were approximately the same as those obtained when using the McDonald criteria, although with a smaller spatial extension. Our results are also consistent with those of previous studies in patients with a FCDE that compared topographical lesion frequency in those who converted to CDMS versus non-converting patients [9,13–15]. Furthermore, in patients with

**TABLE 2** Percentage reduction in the number of new/enlarging and shrinking/disappearing lesions in specific white matter regions of patients who converted to McDonald multiple sclerosis versus patients who did not convert

| Tract         | New/enlarging lesions, mean ± SD | Shrinking/disappearing lesions, mean ± SD |
|---------------|----------------------------------|------------------------------------------|
|               | Patients converting to McDonald MS | Non-converting patients | Percentage reduction, % | Patients converting to McDonald MS | Non-converting patients | Percentage reduction, % |
| ATR           | 1.12 ± 1.9                       | 0.19 ± 0.6***                       | 83                  | 0.89 ± 1.4                       | 0.33 ± 1.0***                       | 63                  |
| Cingulum      | 0.35 ± 1.0                       | 0.02 ± 0.1***                       | 94                  | 0.26 ± 0.7                       | 0.05 ± 0.2***                       | 81                  |
| CST           | 0.84 ± 1.3                       | 0.16 ± 0.4***                       | 81                  | 0.76 ± 1.2                       | 0.23 ± 0.5***                       | 70                  |
| Forceps major | 0.50 ± 1.0                       | 0.13 ± 0.6***                       | 74                  | 0.36 ± 0.8                       | 0.18 ± 0.5**                        | 50                  |
| Forceps minor | 0.30 ± 0.8                       | 0.01 ± 0.1***                       | 97                  | 0.22 ± 0.6                       | 0.06 ± 0.3***                       | 73                  |
| IFOF          | 1.06 ± 1.8                       | 0.22 ± 0.7***                       | 79                  | 0.66 ± 1.2                       | 0.25 ± 0.8***                       | 62                  |
| ILF           | 0.79 ± 1.5                       | 0.14 ± 0.4***                       | 82                  | 0.46 ± 1.0                       | 0.20 ± 0.8**                        | 56                  |
| SLF           | 1.34 ± 2.2                       | 0.21 ± 0.6***                       | 84                  | 0.95 ± 1.7                       | 0.26 ± 0.6***                       | 73                  |
| UF            | 0.12 ± 0.4                       | 0.01 ± 0.1**                        | 92                  | 0.05 ± 0.2                       | 0.01 ± 0.1*                        | 80                  |

Note: Regions considered were based on the Johns Hopkins University White-Matter Tractography Atlas.

Abbreviations: ATR, anterior thalamic radiation; CST, cortical spinal tract; IFOF, inferior fronto-occipital fasciculus; ILF, inferior longitudinal fasciculus; MS, multiple sclerosis; SD, standard deviation; SLF, superior longitudinal fasciculus; UF, uncinate fasciculus.

*p < 0.05, **p < 0.01, ***p < 0.001 versus converting group.
early relapsing-remitting MS, sustained disease progression, when compared with stable disease, was initially associated with significantly greater T2 lesion volume and whole brain, subcortical deep grey matter, WM and cortical volume, and significantly larger decreases in whole brain, cortex, grey matter, and thalamus volume over a 5-year period [16].

At follow-up, treatment with sc IFN β-1a had no effect on shrinking/disappearing lesions but significantly reduced the number and volume of new/enlarging lesions compared with placebo. These data align with the primary findings from the REFLEX clinical trial, which used conventional MRI techniques to determine the number and volume of new T2 lesions in patients treated with sc IFN β-1a qw or tiw versus placebo [2]. The lack of treatment effect on shrinking/disappearing lesions would be difficult to detect given that the voxel-wise analysis was performed on areas of low lesion frequency in patients with a relatively low lesion load at baseline. However, since it is thought that different pathological mechanisms are responsible for new/enlarging and shrinking/disappearing lesions [17], it is possible that sc IFN β-1a mostly reduces inflammation rather than directly promoting repair of tissue damage, although we are unable to confirm this based on our findings. Our study identified only a few specific WM regions where inflammatory activity was more pronounced in the placebo-treated than in the sc IFN β-1a-treated group, but the absence of treatment-by-tract interactions suggests that sc IFN β-1a targets brain areas with a high presence of inflammatory activity irrespective of tract. These results complement those of Vrenken et al. [18] who showed that treatment with sc IFN β-1a 44 μg tiw, but not qw, reduced evolution of the absolute number of new lesions into black holes in patients with a FCDE.
Strengths and limitations

The present analysis used MRI-based LPMs generated from SubI to assess treatment effect in a clinical trial. SubI has multiple advantages for monitoring lesion evolution in WM regions of the brain, as it is a more sensitive technique compared with conventional, single time-point imaging [3]. This is particularly important in a clinical setting for deciphering treatment effects on disease activity. SubI also allows in-depth characterization of lesion activity, by enabling the differentiation between new and enlarging, shrinking, and disappearing lesions. This is advantageous over conventional MRI techniques that only measure net volume change [3]. In addition, use of SubI is less time consuming compared with other methods, since measurements are obtained from a single image rather than analysis of individual images at different time-points. Since SubI enhances study power, fewer subjects are required than with conventional techniques [19]. Nevertheless, the findings of this study were based on a very complete set of analyses obtained in parallel from a well-defined set of more than 100 patients with early MS.

Despite these strengths, some limitations must be acknowledged. A very precise overlap of lesions was not required in the tract analysis, and lesions were only counted provided they resided in a specific tract. A clear mechanistic explanation for the observed anatomical distribution of lesion changes is also lacking. In addition, these analyses were post hoc and the calculated p values are therefore descriptive in nature with no adjustment for multiple testing. Finally, a plausible explanation of our results cannot exclude the greater statistical power of the LPM analysis in those regions where the incidence of injury is greatest. Figure 4 shows the LPM of the 407 patients employed in the longitudinal lesion analysis both at

| Tract            | Lesions in sc IFN β-1a-treated patients, mean ± SD | Lesions in placebo-treated patients, mean ± SD | Percentage reduction, % |
|------------------|--------------------------------------------------|-----------------------------------------------|-------------------------|
| ATR              | 0.72±1.5                                         | 1.22±2.0*                                     | 41                      |
| Cingulum         | 0.17±0.6                                         | 0.46±1.2**                                    | 63                      |
| CST              | 0.53±1.1                                         | 0.96±1.4**                                    | 45                      |
| Forceps Major    | 0.35±0.8                                         | 0.51±1.0                                      | 31                      |
| Forceps Minor    | 0.18±0.6                                         | 0.34±0.9                                      | 47                      |
| IFOF             | 0.71±1.5                                         | 1.13±1.9                                      | 37                      |
| ILF              | 0.49±1.1                                         | 0.91±1.6*                                     | 46                      |
| SLF              | 0.83±1.6                                         | 1.53±2.5**                                    | 46                      |
| UF               | 0.08±0.4                                         | 0.12±0.3                                      | 33                      |

Note: Regions considered were based on the Johns Hopkins University White-Matter Tractography Atlas.

Abbreviations: ATR, anterior thalamic radiation; CST, cortical spinal tract; IFOF, inferior fronto-occipital fasciculus; IFN, interferon; ILF, inferior longitudinal fasciculus; sc, subcutaneous; SD, standard deviation; SLF, superior longitudinal fasciculus; UF, uncinate fasciculus. *p < 0.05, **p < 0.01 versus sc IFN β-1a-treated patients.

Figure 3: Voxel cluster analysis in placebo-treated versus subcutaneous interferon beta-1a (sc IFN β-1a)-treated patients. Clusters of voxels where new brain lesions were more frequent in placebo- versus sc IFN β-1a-treated patients (controlled for age, sex, and center; top row). Colour overlap created on top of the Montreal Neurological Institute standard brain registered on the study-specific template showing the tracts considered (bottom row). ATR, anterior thalamic radiation; CST, cortical spinal tract; FM, forceps major; Fm, forceps minor; ILF, inferior longitudinal fasciculus; SLF, superior longitudinal fasciculus. [Colour figure can be viewed at wileyonlinelibrary.com]
disappearing lesions between the treated and non-treated groups both at global and voxel-wise levels. In parallel work on the same dataset [18], new black hole lesions were found to be less likely to develop in sc IFN β-1a-treated patients, although this seemed to be driven by an overall reduction of development of new lesions. This is in line with the findings reported here, which suggest that sc IFN β-1a does not promote lesion repair. Further analyses could be performed to investigate the spatio-temporal relationship between new lesion appearance and atrophy in driving the conversion from FCDE to MS, and how long-term treatment with sc IFN β-1a can delay this conversion. In this regard, studies with a longer follow-up are needed to evaluate the predictive value of the early changes observed in these analyses, and to assess how they are related to conversion to McDonald MS and CDMS. The MRI-based LPM generated from the Subl approach used in this manuscript could be used in further studies given its sensitivity and convenience.

**ACKNOWLEDGMENTS**

This study was supported by Merck (CrossRef Funder ID: 10.13039/100009945) with a joint grant to the University of Siena, Siena, Italy and the Amsterdam UMC (Location VUMc), Amsterdam, The Netherlands. Medical writing support was provided by Sarah Wetherill, Caroline Spencer, and Steve Winter of inScience Communications, Springer Healthcare Ltd, UK, and funded by Merck Healthcare KGaA, Darmstadt, Germany. Frederik Barkhof acknowledges support from the NIHR Biomedical Research Centre at UCLH. Open Access Funding provided by Universita degli Studi di Siena within the CRUI-CARE Agreement.

**CONFLICT OF INTEREST**

HV has received research support from Merck, Novartis, Pfizer, and Teva, consulting fees from Merck, and speaker honoraria from Novartis; all funds were paid to his institution. AV has received research support from Merck. MSF has received honoraria or consultation fees from Alexion, Atara Biotherapeutics, Bayer, BiGene, BMS (Cellgene), EMD Inc., Canada (an affiliate of Merck KGaA), Hoffmann-La-Roche, Janssen (J&J), Merck, Novartis, Pendumharm, and Sanofi-Genzyme; has been a member of a company advisory board, board of directors, or other similar group for Alexion, Atara Biotherapeutics, Bayer, BiGene, BMS (Cellgene), Clene Nanomedicine, Hoffmann-La-Roche, Janssen (J&J), McKesson, Merck, Novartis, and Sanofi-Genzyme; and has participated in a company sponsored speaker’s bureau for EMD Serono Inc., USA (an affiliate of Merck KGaA) and Sanofi-Genzyme. BMJU has received consultation fees from Biogen, Genzyme, Merck, Novartis, Roche, and Teva. LK’s institution (University Hospital, University of Basel) has received the following exclusively for research support: steering committee, advisory board, and consultancy fees (Actelion [Janssen/J&J], Bayer, Biogen, BMS, Genzyme, Janssen, Merck, Novartis, Roche, Sanofi, Santhera, and TG Therapeutics); speaker fees (Bayer, Biogen, Merck, Novartis, Roche, and Sanofi); support of educational activities (Allergan, Bayer, Biogen, CSL Behring, Desitin, Genzyme, Merck, Novartis, Roche, Pfizer, Sanofi, Shire, and Teva); license fees for Neurostatus products;
and grants (Bayer, Biogen, European Union, InnoSwiss, Merck, Novartis, Roche, Swiss MS Society, and Swiss National Research Foundation). GC has received consulting fees from Bayer, Biogen, Merck, Novartis, Receptos, Roche/Genentech, Sanofi-Aventis, and Teva Pharmaceutical Industries Ltd; lecture fees from Bayer, Biogen, Merck, Novartis, Sanofi-Aventis, Serono Symposia International Foundation, and Teva Pharmaceutical Industries Ltd; and trial grant support from Bayer, Biogen, Merck, Novartis, Receptos, Roche/Genentech, Sanofi-Aventis, and Teva Pharmaceutical Industries Ltd. AS is an employee of Merck Healthcare KGaA, Darmstadt, Germany. DJ is an employee of Merck Serono Ltd, Feltham, UK (an affiliate of Merck KGaA). MPS has received consulting fees from Biogen, GeNeuro, Genzyme, MedDay, Merck, Novartis, Roche, and Teva. FB is supported by the NIHR Biomedical Research Centre at UCLH and is a consultant to Biogen, Combinostics, IXICO, Merck, and Roche. NDeS is a consultant for Biogen, Merck, Novartis, Roche, Sanofi-Genzyme, and Teva; has grants or grants pending from FISM and Novartis, is on the speakers’ bureaus of Biogen, Merck, Novartis, Roche, Sanofi-Genzyme, and Teva; and has received travel funds from Merck, Novartis, Roche, Sanofi-Genzyme, and Teva. MB, RTB, GG, and LL report no disclosures.

AUTHOR CONTRIBUTIONS
Marco Battaglini: Conceptualization (equal); Investigation (equal); Methodology (equal); Software (equal); Supervision (equal); Writing – original draft (equal). Hugo Vrenken: Conceptualization (equal); Investigation (equal); Methodology (equal); Software (equal); Supervision (equal); Writing – original draft (equal). Riccardo Tappa Brocci: Validation (equal); Writing – review & editing (equal). Giordano Gentile: Software (equal); Validation (equal); Writing – review & editing (equal). hugo Versteeg: Writing – review & editing (equal). Mark S. Freedman: Writing – review & editing (equal). bernard M. J. uittendaag: Writing – review & editing (equal). ludwig Kappos: Writing – review & editing (equal). Giancarlo Comi: Writing – review & editing (equal). Andrea Seitinger: Writing – review & editing (equal). Dominic Jack: Writing – review & editing (equal). Maria Pia Sormani: Writing – review & editing (equal). Frederik Barkhof: Conceptualization (equal); Investigation (equal); Supervision (equal); Writing – review & editing (equal). Nicola De Stefano: Conceptualization (equal); Investigation (equal); Supervision (equal); Writing – review & editing (equal).

ETHICAL APPROVAL
This post hoc study used data from the REFLEX trial, which was undertaken in compliance with the Declaration of Helsinki and standards of Good Clinical Practice according to the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. For each center, the relevant institutional review board or independent ethics committee reviewed and approved the trial protocol, patient information leaflet, informed consent forms, and investigator brochure. Written informed consent was obtained for all patients at the screening visit.

DATA AVAILABILITY STATEMENT
Any requests for data by qualified scientific and medical researchers for legitimate research purposes will be subject to Merck's Data Sharing Policy. All requests should be submitted in writing to Merck's data sharing portal https://www.merckgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html. When Merck has a co-research, co-development, or co-marketing or co-promotion agreement, or when the product has been out-licensed, the responsibility for disclosure might be dependent on the agreement between parties. Under these circumstances, Merck will endeavour to gain agreement to share data in response to requests.

ORCID
Marco Battaglini https://orcid.org/0000-0002-9188-4408 Giordano Gentile https://orcid.org/0000-0002-8481-2801 Giancarlo Comi https://orcid.org/0000-0002-6989-1054 Andrea Seitinger https://orcid.org/0000-0001-8088-9695 Dominic Jack https://orcid.org/0000-0001-8629-553X Frederik Barkhof https://orcid.org/0000-0003-3543-3706

REFERENCES
1. Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol. 2012;11:33-41.
2. De Stefano N, Comi G, Kappos L, et al. Efficacy of subcutaneous interferon beta-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry. 2014;85:647-653.
3. Duan Y, Hildenbrand PG, Sampat MP, et al. Segmentation of subtraction images for the measurement of lesion change in multiple sclerosis. Am J Neuroradiol. 2008;29:340-346.
4. Di Perri C, Battaglini M, Stromillo ML, et al. Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis. Arch Neurol. 2008;65:236-243.
5. Tintore M, Rovira A, Rio J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology. 2006;67:968-972.
6. Ruiz A, Deloire MS, Ouallet JC, Molinder S, Brochet B. Predictive factors for multiple sclerosis in patients with clinically isolated spinal cord syndrome. Mult Scler. 2011;17:312-318.
7. The Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. 2008;65:727-732.
8. Fisniku LK, Brex PA, Altman DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008;131:808-817.
9. Giorgio A, Battaglini M, Rocca MA, et al. Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. Neurology. 2013;80:234-241.
10. Vellinga MM, Geurts JJ, Rostrup E, et al. Clinical correlations of brain lesion distribution in multiple sclerosis. J Magn Reson Imaging. 2009;29:768-773.
11. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58:840-846.
12. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227-231.
13. Bendfeldt K, Taschler B, Gaetano L, et al. MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry. Brain Imaging Behav. 2019;13:1361-1374.
14. Dalton CM, Bodini B, Samson RS, et al. Brain lesion location and clinical status 20 years after a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler. 2012;18:322-328.
15. Gaetano L, Magnusson B, Kindalova P, et al. White matter lesion location correlates with disability in relapsing multiple sclerosis. Mult Scler J Exp Transl Clin. 2020;6:2055217320906844.
16. Zivadinov R, Bergsland N, Dolezal O, et al. Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years. Am J Neuroradiol. 2013;34:1931-1939.
17. Pongratz V, Schmidt P, Bussas M, et al. Prognostic value of white matter lesion shrinking in early multiple sclerosis: an intuitive or naïve notion? Brain Behavior. 2019;9:e01417.
18. Vrenken H, de Vos ML, Battaglini M, et al. Evolution of new lesions and its temporal patterns in patients with clinically isolated syndrome treated with subcutaneous interferon beta-1a [P1025]. Mult Scler. 2017;23(5):529-530.
19. Moraal B, Meier DS, Poppe PA, et al. Subtraction MR images in a multiple sclerosis multicenter clinical trial setting. Radiology. 2009;250:506-514.

**SUPPORTING INFORMATION**
Additional supporting information may be found in the online version of the article at the publisher’s website.

**How to cite this article:** Battaglini M, Vrenken H, Tappa Brocci R, et al. Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a. Eur J Neurol. 2022;29:2024–2035. doi:10.1111/ene.15314